Rare diseases
Investigational molecules
Locations
Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus
BulgariaDoxycycline post‑exposure prophylaxis for sexually transmitted infections in MSM and transgender women on antiretroviral drug combination
SpainSwitching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study
FranceA study of islatravir and ulonivirine for adults with HIV who have not received previous treatment
FranceA study testing VH4524184 with emtricitabine and tenofovir alafenamide compared to dolutegravir and lamivudine in adults with HIV-1 who have not received treatment before
BelgiumStudy on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment
CzechiaStudy on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis
AustriaStudy Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy
FranceSafety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1
GermanyPhase III trial evaluating ianalumab with background drug combination in patients with Sjögren's disease
AustriaStudy of Emtricitabine, Tenofovir Alafenamide and Bictegravir in Adults with HIV Undergoing Analytical Treatment Interruption
SpainStudy of Weekly Oral GS-1720 and GS-4182 for People with HIV-1 Who Are Virologically Suppressed
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
